Nov 16, 2021 01:00 MST
November 16, 2021(Newswire.com) –
InDevR, Inc., a lifestyle science instruments firm delivering effective analytical technologies to help the progress and production of vaccines and biotherapeutics, introduced commercial availability of its new ArrayMaxTM Mixer to deliver drastically reduced assay instances for its VaxArray® Portfolio of immunoassay kits.
Recent VaxArray Assays consist of kits for influenza, coronavirus, measles/rubella, and polio, and provide vaccine companies more quickly characterization of identity, quantity, and stability parameters in the course of manufacture and release of vaccine products. The ArrayMax Mixer drastically enhances mixing in excess of static incubation or regular orbital shakers for the duration of assay execution applying possibly antibody or antigen samples. In internal validation studies comparing ArrayMax to authentic VaxArray protocols, identical or improved analytical functionality was obtained making use of new ArrayMax-executed VaxArray protocols and up to an 85% reduction of time to end result was received.
In a little 6″x 6″ footprint, this hassle-free new resource provides the risk to make VaxArray outcomes in a portion of the time compared to standard ELISA, offering a complete assay time of considerably less than one hour for currently offered VaxArray Kits. As an instance, the VaxArray Influenza Seasonal HA Assay earlier experienced an approximate 2.5 hour time to consequence such as sample planning. Using the ArrayMax Mixer, the total assay time was minimized to < 30 minutes, which provides a 5x faster time to result. Coupled with high throughput multiplex detection of several analytes simultaneously, VaxArray allows incredibly fast, best-in-class immunoassay detection of vaccine products or serology analytes. InDevR also offers custom immunoassay kits for measurement of up to nine analytes, and ArrayMax enables all of these measurements in ~1 hour.
Erica Dawson, CTO of InDevR, noted, “Our VaxArray Assay Kits already provide significant advantages over outdated, laborious, and error prone techniques such as SRID, TCID50, and ELISAs. This further reduction in total assay time for the VaxArray Kits will benefit any vaccine development or manufacturer in bioprocess development, optimization and monitoring, as well as vaccine release testing. We are excited to continue empowering vaccine producers by further expanding our portfolio.”
Terry Salyer, CCO
Email: [email protected]
Source: InDevR, Inc.